Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy

scientific article

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2013PLoSO...855038V
P356DOI10.1371/JOURNAL.PONE.0055038
P932PMC publication ID3557242
P698PubMed publication ID23383047
P5875ResearchGate publication ID235402969

P50authorSamir AbdurahmanQ55173050
Staffan NilssonQ55457264
Tatsuo KandaQ61112129
Magnus GisslénQ90302675
Anders SönnerborgQ90893354
Piotr NowakQ37841236
Jessica NyströmQ42996907
P2093author name stringLars-Magnus Andersson
Jan Vesterbacka
Hiroyuki Funaoka
Babilonia Barqasho
P2860cites workEmerging concepts in the immunopathogenesis of AIDSQ22241984
Microbial translocation is a cause of systemic immune activation in chronic HIV infectionQ22251054
Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapyQ46481116
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapyQ46812278
A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP.Q48023468
Immune reconstitution in HIV+ subjects on lopinavir/ritonavir-based HAART according to the severity of pre-therapy CD4+.Q48658905
Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study.Q51058766
Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.Q54415328
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell countQ56334717
Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utilityQ79175503
Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitisQ80507477
Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosisQ82223323
Development of a high-specificity sandwich ELISA system for the quantification of human intestinal fatty acid-binding protein (I-FABP) concentrationsQ83122025
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical eventsQ32025738
Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiomeQ33547430
Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patientsQ33816212
Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapyQ33873507
Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDSQ33873798
Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapyQ33924628
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural UgandaQ34359439
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapyQ34384134
Plasma levels of soluble CD14 independently predict mortality in HIV infectionQ34764002
Impact of HMGB1/TLR Ligand Complexes on HIV-1 Replication: Possible Role for Flagellin during HIV-1 InfectionQ36032021
In vitro and in vivo effects of HIV protease inhibitors on apoptosisQ36068283
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyQ36499290
HIV protease inhibitors impact on apoptosis.Q37066766
Flagellin as an adjuvant: cellular mechanisms and potential.Q37130379
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.Q37207653
Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factorsQ37290836
Cardiovascular disease and HIV infection: host, virus, or drugs?Q37521745
Bacterial flagellin is a dominant antigen in Crohn disease.Q37698878
Role of CD14 in lung inflammation and infectionQ37710762
Long-term impacts of antibiotic exposure on the human intestinal microbiotaQ37779673
Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infectionQ37862747
Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicityQ37869166
Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapyQ38440519
Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitorQ39652630
Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept studyQ42551648
Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy.Q42970792
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patientsQ43067974
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patientsQ43228365
The role of CD14 gene promoter polymorphism in tuberculosis susceptibilityQ44183724
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimensQ44660024
Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapyQ44871108
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluationQ46157814
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectlopinavirQ422585
efavirenzQ422645
anti-retroviral agentQ50430310
P304page(s)e55038
P577publication date2013-01-28
P1433published inPLOS OneQ564954
P1476titleKinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy
P478volume8

Reverse relations

cites work (P2860)
Q38856670Brief Report: Differential Associations of Interleukin 6 and Intestinal Fatty Acid-Binding Protein With Progressive Untreated HIV-1 Infection in Rakai, Uganda.
Q35945416Complexities of Gut Microbiome Dysbiosis in the Context of HIV Infection and Antiretroviral Therapy
Q33599291Contribution of intestinal barrier damage, microbial translocation and HIV-1 infection status to an inflammaging signature
Q92827882Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation
Q35283132Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting
Q36957752Inflammation, immune activation, and cardiovascular disease in HIV.
Q93147271Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial
Q35191924Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
Q57111128Lower pretreatment gut integrity is independently associated with fat gain on antiretroviral therapy
Q36558287Microbial translocation in the pathogenesis of HIV infection and AIDS.
Q37516139Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden
Q33727042Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection
Q64902148Reduced Transplacental Transfer of Antimalarial Antibodies in Kenyan HIV-Exposed Uninfected Infants.
Q40121502Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers
Q36957941Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals
Q33934080Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial
Q46945781Very Early ART and Persistent Inflammation in Treated HIV.

Search more.